Bioextrax (BIOEX.ST) Stock Analysis & AI Equity Report
Bioextrax (BIOEX.ST) overview
Bioextrax (BIOEX.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Bioextrax reported revenue of SEK 0.5m and operating profit of SEK -17.5m; the year-end share price was 3.64 SEK and market capitalisation was SEK 121m. Bioextrax is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bioextrax's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Bioextrax
Bioextrax AB is a Swedish biotechnology company that develops and licenses patented, chemical-free processes for producing biobased materials. Its main activities include PHA-based bioplastics and the upcycling of poultry feather waste into protein hydrolysates and keratin microfibres. The company works with partners to commercialise its technologies across industrial applications.
Generate the Bioextrax report
Bioextrax is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Bioextrax and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.